本文選題：檢查點(diǎn)　切入點(diǎn)：黑色素瘤　出處：《中國(guó)免疫學(xué)雜志》2017年04期

【摘要】：正免疫檢查點(diǎn)阻斷治療是當(dāng)今備受矚目的新興腫瘤治療方式。不同于以往其他治療方式,免疫檢查點(diǎn)抑制劑靶向機(jī)體免疫系統(tǒng)而非腫瘤細(xì)胞,旨在恢復(fù)并促進(jìn)效應(yīng)T細(xì)胞特異性識(shí)別和殺傷腫瘤細(xì)胞的功能,系統(tǒng)性增強(qiáng)全身的抗腫瘤免疫反應(yīng),因而代表了當(dāng)前腫瘤治療模式的轉(zhuǎn)變。迄今多個(gè)臨床試驗(yàn)已證實(shí)免疫檢查點(diǎn)抑制劑在晚期黑色素瘤、非小細(xì)胞肺癌(Non-small-cell lung cancer,NSCLC)及膀胱
[Abstract]:The positive immunological checkpoint blocking therapy is one of the most popular methods for the treatment of neoplasms. Unlike other treatments, immunocheckpoint inhibitors target the body's immune system rather than tumor cells. The aim is to restore and promote the function of specific recognition and killing of tumor cells by effector T cells, and to systematically enhance the anti-tumor immune response of the whole body. So far, a number of clinical trials have confirmed immunological checkpoint inhibitors in advanced melanoma, non-small- cell lung cancer-NSCLC) and bladder.
【作者單位】： 上海交通大學(xué)醫(yī)學(xué)院附屬仁濟(jì)醫(yī)院婦產(chǎn)科上海市婦科腫瘤重點(diǎn)實(shí)驗(yàn)室;
【基金】：國(guó)家自然科學(xué)基金面上項(xiàng)目(81472843) 上海市科學(xué)技術(shù)委員會(huì)上海市科研計(jì)劃項(xiàng)目(14ZR1424700)資助
【分類號(hào)】：R730.51

【相似文獻(xiàn)】

相關(guān)期刊論文 前1條

1 付s，

本文編號(hào)：1684568